<table>
<thead>
<tr>
<th>Time</th>
<th>Track 1</th>
<th>Track 2</th>
<th>Track 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration, Breakfast and Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:55am</td>
<td><strong>Ralph Snyderman, Duke University</strong> Opening words by program chair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00am</td>
<td><strong>Peter Donnelly, Oxford University</strong> PMWC 2015 UK Introduction and Overview</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:05am</td>
<td><strong>Amir Dan Rubin, Stanford Health Care</strong> Stanford Health Care Delivery Innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15am</td>
<td><strong>Craig Venter, JCVI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30am</td>
<td><strong>Ron Davis, Stanford University</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45am</td>
<td><strong>George Church, Harvard Medical School</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Newborn &amp; Prenatal Dx</strong></td>
<td><strong>Cardiovascular Disease &amp; Biomarkers</strong></td>
<td><strong>Dx/Rx Company Competition</strong></td>
</tr>
<tr>
<td>9:00am</td>
<td><strong>Matthew Rabinowitz, Natera (Chair)</strong></td>
<td><strong>Gil Omenn, University of Michigan (Chair)</strong></td>
<td><strong>Dx/Rx Company Competition</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Dennis Lo, Li Ka Shing Institute</strong></td>
<td><strong>Cardiovascular Diseases Reflect Many Modifiable Risk Factors and Multiple Predisposing Gene</strong></td>
<td><strong>Andy Kurtz, NCI</strong></td>
</tr>
<tr>
<td>9:15am</td>
<td><strong>Susan Gross, Natera</strong></td>
<td><strong>Jennifer Van Eyk, Cedars-Sinai</strong></td>
<td><strong>Accel Diagnostics</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Identifying Constellations in Cell-Free DNA</strong></td>
<td><strong>Disease Modified Proteins: Link between Rheumatic Arthritis and Heart Disease</strong></td>
<td></td>
</tr>
<tr>
<td>9:30am</td>
<td><strong>Vince Ramey, DNAnexus</strong></td>
<td><strong>Jay G. Wohlgemuth, Quest Diagnostics</strong></td>
<td><strong>ACD Bio</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Addressing Operational Challenges of Prenatal Testing Such as Scalability and Global Data Access</strong></td>
<td><strong>Holistic and Integrated Cardiovascular Diagnostic Solution</strong></td>
<td></td>
</tr>
<tr>
<td>9:45am</td>
<td><strong>Ramji Srinivasan, Counsyl</strong></td>
<td><strong>Robert Gerszten, MGH Heart Center</strong></td>
<td><strong>APT Life Sciences</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Next Generation Counseling: Reinventing Results Delivery</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00am</td>
<td>Break, Exhibition &amp; Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Impact of Genomics on Cancer Care</strong></td>
<td><strong>Commercializing Longevity &amp; Aging Genetics</strong></td>
<td><strong>Dx/Rx Company Competition (Cont.)</strong></td>
</tr>
<tr>
<td>10:30am</td>
<td><strong>Frank S. Ong, Illumina (Chair)</strong></td>
<td><strong>Brian Kennedy, Buck Institute (Chair)</strong></td>
<td><strong>Dx/Rx Company Competition (Cont.)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>John Leite, Illumina</strong></td>
<td><strong>Drugs That Forestall Aging – Extending Healthspan</strong></td>
<td></td>
</tr>
<tr>
<td>10:45am</td>
<td><strong>Mike Nolan, Thermo Fisher Scientific</strong></td>
<td><strong>Felix Frueh, Human Longevity</strong></td>
<td><strong>Biological Dynamics</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Pioneering the Path to Precision Oncology Through Next-Generation Sequencing</strong></td>
<td><strong>Healthy Aging and the Capture of Converging Technologies</strong></td>
<td><strong>Bullet Bio</strong></td>
</tr>
<tr>
<td>11:00am</td>
<td><strong>Brad Gray, NanoString Technologies</strong></td>
<td><strong>Elli Kaplan, Neurotrack</strong></td>
<td><strong>Dermala</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Improving Cancer Care Through Localized Tumor Profiling</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15am</td>
<td><strong>Mark Erlander, Trovagene</strong></td>
<td><strong>Emili Conley, 23andMe</strong></td>
<td><strong>GenePeeks</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples</strong></td>
<td><strong>Accelerating Research Through Big Data</strong></td>
<td></td>
</tr>
<tr>
<td>11:30am</td>
<td><strong>Tom Willis, Sequenta</strong></td>
<td><strong>Panel, Q&amp;A</strong></td>
<td><strong>Moleculera Labs</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Immune Response Profiling: Actionable Insights Through Next-Gen Sequencing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45am</td>
<td>Audience Q&amp;A</td>
<td></td>
<td><strong>Novellus Dx</strong></td>
</tr>
<tr>
<td>12:00pm</td>
<td>Lunch, Exhibition &amp; Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Track 1</td>
<td>Track 2</td>
<td>Track 3</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>1:00pm</td>
<td>Clinical Methodologies of NGS</td>
<td>Applications of NGS for Non-oncology</td>
<td>Dx/Rx Company Competition (Cont.)</td>
</tr>
<tr>
<td></td>
<td>Mike Snyder, Stanford University (Chair)</td>
<td>Cliff Reid, Complete Genomics (Chair)</td>
<td>Prime Genomics</td>
</tr>
<tr>
<td></td>
<td>Analyzing Complex Diseases Using Integrative Omics Technologies</td>
<td>Whole Genome Sequencing for Diagnosing Intellectual Disability</td>
<td>Sandstone Diagnostics</td>
</tr>
<tr>
<td>1:15pm</td>
<td>Patrick Roche, HTG Molecular</td>
<td>Cornelius Baerkoel, Appistry</td>
<td>Genomic Centers</td>
</tr>
<tr>
<td></td>
<td>NGS-based Molecular Profiling from a Single FFPE Section</td>
<td>Personalized Medicine: A Communal Affair</td>
<td>Peter Donnelly, Oxford University</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Michael Ball, GenoLogics</td>
<td>Patrice Milos, Claritas Genomics</td>
<td>Genomic Centers</td>
</tr>
<tr>
<td></td>
<td>The Impact of Informatics on Clinical NGS Services</td>
<td>Successes and Challenges of Spinning out an Academic Genetic Testing Laboratory</td>
<td>Somalee Datta, Stanford University</td>
</tr>
<tr>
<td>1:45pm</td>
<td>Jason Merker, Stanford University School of Medicine</td>
<td>Jonas Korlach, Pacific Biosciences</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Using Genome Sequencing in the Clinical Setting</td>
<td>New views of the Human Genome &amp; Transcriptome through Long-Read Sequencing</td>
<td></td>
</tr>
<tr>
<td>2:00pm</td>
<td>John Ryals, Metabolon, Inc.</td>
<td>Michael Ball, GenoLogics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Getting More from NGS: Metabolomics as a First-line Phenotyping Tool</td>
<td>The Impact of Informatics on Clinical NGS Services</td>
<td></td>
</tr>
<tr>
<td>2:15pm</td>
<td>Impact of Genomics on Cancer Care (Cont.)</td>
<td>Clinical Trials in the Era of PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frank S. Ong, Illumina (Chair)</td>
<td>Steven Stein, Novartis (Chair)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kim Popovits, Genomic Health</td>
<td>Flipping the Clinical Trial Paradigm 180 Degrees</td>
<td>Berta Strulovici, WI, Israel</td>
</tr>
<tr>
<td></td>
<td>Transforming the Cancer Patient Journey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30pm</td>
<td>Janusz Dukowski, Data4Cure</td>
<td>Nathan Caffo, Presage Biosciences</td>
<td>John Witte, UCSF Human Genetics Inst.</td>
</tr>
<tr>
<td></td>
<td>Personal Systems Interpretation: a Multidimensional View Into Cancer</td>
<td>Human Patients: The Most Important Cancer Model</td>
<td></td>
</tr>
<tr>
<td>2:45pm</td>
<td>Martin Naley, Cure Forward</td>
<td>Eran Eden, MeMed</td>
<td>Marc LePage, Génome Québec</td>
</tr>
<tr>
<td></td>
<td>The Coming Genomics Boom: Will Patients Be The Catalyst?</td>
<td>Relying on the Most Accurate System to Diagnose Infections... Your Immune System</td>
<td></td>
</tr>
<tr>
<td>3:00pm</td>
<td>Break, Exhibition &amp; Networking</td>
<td>Impact of Genomics on Cancer Care (Cont.)</td>
<td>Genomic Centers (Cont.)</td>
</tr>
<tr>
<td>3:15pm</td>
<td>Impact of Genomics on Cancer Care (Cont.)</td>
<td>Clinical Trials in the Era of PM (Cont.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael Pellini, Foundation Medicine (Chair)</td>
<td>David Dvoracezyk, Oracle</td>
<td>Radoje Drmanac, BGI Research</td>
</tr>
<tr>
<td></td>
<td>“Comprehensive” Molecular Profiling And Big Data Is Changing The Fight Against Cancer</td>
<td>Improving Drug Discovery and Development with Genomics</td>
<td></td>
</tr>
<tr>
<td>3:30pm</td>
<td>Nicholas Dracopoli, Janssen R&amp;D</td>
<td>Andy Kogelnik, Open Medicine Institute (OMI)</td>
<td>Andrew Barry, Broad Institute</td>
</tr>
<tr>
<td></td>
<td>Circulating Tumor Cells: From Enumeration to Comprehensive Characterization</td>
<td>Clinical Trials in the Age of Social Media</td>
<td></td>
</tr>
<tr>
<td>3:45pm</td>
<td>Stefan Roever, Genia</td>
<td>Ann Kapoun, OncoMed</td>
<td>Olena Morozov, UCSC GX Inst.</td>
</tr>
<tr>
<td></td>
<td>Krishna Yeshwant, Google Ventures</td>
<td>Patient Selection Approaches Using Protein and Gene Predictive Biomarkers; 2 Case Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel, Q&amp;A</td>
<td>Rami Kåkonen, Medisapiens (US) Inc.</td>
<td>Nathan Pearson, New York Genome Center</td>
</tr>
<tr>
<td>4:00pm</td>
<td></td>
<td>Remission Coach: A New Platform to Enable Targeted Recruiting for Clinical Trials</td>
<td></td>
</tr>
<tr>
<td>4:15pm</td>
<td></td>
<td>Rebecca Blanchard, Merck</td>
<td></td>
</tr>
<tr>
<td>4:30pm</td>
<td></td>
<td>Incorporating PGx Research Into Clinical Drug Development</td>
<td></td>
</tr>
<tr>
<td>4:45pm</td>
<td></td>
<td>George Sledge, Stanford University</td>
<td>Mya Thomae, Illumina</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genomics Chaos and the Cancer Therapy Spectrum</td>
<td>Tutorial: FDA Update: LDTs, CoDx &amp; NGS</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Tom Caskey, Baylor College of Medicine</td>
<td>Executive Care for Genetic Disease Prevention</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Audience Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>5:15pm</td>
<td>Closing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Track 1</td>
<td>Track 2</td>
<td>Track 3</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td><strong>Time Track 1</strong></td>
<td><strong>Time Track 2</strong></td>
<td><strong>Time Track 3</strong></td>
</tr>
<tr>
<td>7:00am</td>
<td>Registration, Breakfast and Networking</td>
<td>Detection and Molecular Analysis of Drug-induced Adverse Events</td>
<td>Podium Company Presentations</td>
</tr>
<tr>
<td>7:45am</td>
<td><strong>Lee Hood, Institute for Systems Biology</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td>Catalyzing a Revolution in Healthcare through a Longitudinal, Digital-Age Study of 100,000 Well Individuals</td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>8:15am</td>
<td><strong>Ralph Snyderman, Duke University (Chair)</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td>PM &amp; Healthcare Delivery: Value &amp; Cost of Innovation</td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>8:30am</td>
<td><strong>Ed Abrahams, PMC (Moderator)</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Stephen Eck, Astellas</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>8:45am</td>
<td><strong>Steve Miller, Express Scripts</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Paul Radensky, McDermott Will &amp; Emery</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>9:00am</td>
<td><strong>Richard Weinshilboum, Mayo Clinic College of Med.</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td>Podium Company Presentations</td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td></td>
<td><strong>Richard Weinshilboum, Mayo Clinic College of Med.</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>9:15am</td>
<td><strong>Ed Abrahams, PMC (Moderator)</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Stephen Eck, Astellas</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>9:30am</td>
<td><strong>Lawrence Lesko, UF (Chair)</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>From Knowledge Innovation to Personalized Pharmacovigilance</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>9:45am</td>
<td><strong>Jerry Parrott, BioMarker Strategies</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Functional Solid Tumor Profiling for Targeted Drug Development</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>10:00am</td>
<td><strong>Podium Company Presentations</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Podium Company Presentations</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>10:30am</td>
<td><strong>Ira Klein, AETNA (Chair)</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Rina Wolf, XIFIN</strong></td>
<td>From Knowledge Innovation to Personalized Pharmacovigilance</td>
<td>Functional Solid Tumor Profiling for Targeted Drug Development</td>
</tr>
<tr>
<td>10:45am</td>
<td><strong>Scott Patterson, Amgen (Chair)</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>The CDx Conundrum: Multiple IVDs, One Biomarker?</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>11:00am</td>
<td><strong>Christopher Jowett, Abbott Molecular</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Key Aspects Required to Support Unification of Companion Diagnostic Development</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>11:15am</td>
<td><strong>Christopher Jowett, Abbott Molecular</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Key Aspects Required to Support Unification of Companion Diagnostic Development</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>11:30am</td>
<td><strong>Eugene Seymour, NanoViricides</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Eradicating Viral Diseases Using 21st Century Technology</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>11:45am</td>
<td><strong>Richard Klausner, Illumina</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Actionable Genome Consortiums to Guide NGS in Clinical Medicine</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>12:00am</td>
<td><strong>Panel, Q&amp;A</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Panel, Q&amp;A</strong></td>
<td>Lawrence Lesko, UF (Chair) Targeted Therapy Drugs: Safety Matters</td>
<td>Jerry Parrott, BioMarker Strategies</td>
</tr>
<tr>
<td>Time</td>
<td>Track 1</td>
<td>Track 2</td>
<td>Track 3</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1:00pm</td>
<td>Navigating Reimbursement for Oncology Patients &amp; Care Teams</td>
<td>Genomic Profiling Moving Into Routine Clinical Care</td>
<td>Podium Company Presentations</td>
</tr>
<tr>
<td>1:15pm</td>
<td>John Steiner, CTCA (Chair)</td>
<td>Neil Barth, Agendia</td>
<td>Richard Janezczko, DxEconomix</td>
</tr>
<tr>
<td></td>
<td>Dane Dickson, Palmetto GBA</td>
<td>Molecular Subtypes in Breast Cancer: Challenging the Subtyping Paradigm</td>
<td>IVD Value-Based Pricing in the Healthcare Reform</td>
</tr>
<tr>
<td></td>
<td>Maurie Markman, CTCA</td>
<td>Jonathan Hirsch, Syapse (Chair)</td>
<td>Farideh Bischoff, Silicon Biosystems</td>
</tr>
<tr>
<td></td>
<td>Panel, Q&amp;A</td>
<td>Jim Ford, Stanford University</td>
<td>DEPAarray Utility in Recovery of Pure Cell Pop. from Complex Tissues</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Personalizing Evidence in the Learning Healthcare System</td>
<td>Lincoln Nadauld, InterMountain</td>
<td>Alastair Malcolm, Applied Microarrays</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thomas Brown, Swedish Cancer Institute</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Howard Burris, Sarah Cannon Research Inst.</td>
<td></td>
</tr>
<tr>
<td>1:45pm</td>
<td></td>
<td>Genomic Profiling Moving Into Routine Clinical Care</td>
<td></td>
</tr>
<tr>
<td>2:00pm</td>
<td></td>
<td>Joe V. Selby, PCORI</td>
<td>William D. Shreader, Edison Pharmaceuticals</td>
</tr>
<tr>
<td>2:15pm</td>
<td></td>
<td>Albert Crescenzo, Thomson Reuters</td>
<td>Valeria Ossovskaya, BioCrypton Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Clinical Genomics Toolkit, Increasing Precision in Genomic Interpretation</td>
<td></td>
</tr>
<tr>
<td>2:30pm</td>
<td></td>
<td>Mara G. Aspinall, Health Catalysts</td>
<td>Podium Company Presentations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diagnostic 5.0: Breaking the Rules to Succeed</td>
<td>Yusuke Tsukahara, Riken Genesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The Pursuit of Personal Genome in Japan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ian Walker, Cancer Research UK</td>
</tr>
<tr>
<td>2:45pm</td>
<td></td>
<td>Rachid Karam, Ambry Genetics</td>
<td>The Cancer Research UK Stratified Medicine Programme: National Screening to National Trials</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Break, Exhibition &amp; Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30pm</td>
<td>Applying Complementary Technologies Towards Biomarker Discovery</td>
<td>Private Company Competition Diagnostics &amp; Therapeutics</td>
<td>Podium Company Presentations</td>
</tr>
<tr>
<td></td>
<td>Bonnie Anderson, Veracyte (Chair)</td>
<td>Laurence Marton (Moderator)</td>
<td>Brian M. Frezza, Emerald Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Giulia C. Kennedy, Veracyte</td>
<td></td>
<td>What Virtualization of The Laboratory Could Mean for The Future of Medicinal Research</td>
</tr>
<tr>
<td></td>
<td>Using Multiple Sources Of High-Dimensional Genomic Data to Build Diagnostic Algorithms</td>
<td></td>
<td>Angel Pizarro, Amazon Web Services</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Security &amp; Compliance of Genomic Data in the Cloud</td>
</tr>
<tr>
<td>3:45pm</td>
<td>Murali Prahalad, Epic Sciences</td>
<td>Judges:</td>
<td>Doug Fisher, Integrated Diagnostics</td>
</tr>
<tr>
<td></td>
<td>CTCs Come of Age as Biomarkers</td>
<td>Isaac Bright, Merieux Developpement</td>
<td>Integrated Diagnostics Overview</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paul Conley, Paladin Capital Group</td>
<td>Paul Radensky, McDermott Will &amp; Emery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simon Greenwood, Roche Venture Fund</td>
<td>Tutorial: Facing Challenges to Successful Commercialization</td>
</tr>
<tr>
<td>4:00pm</td>
<td>John Sninsky, CareDx</td>
<td>Kim Kamdar, Domain Associates</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New Era In Post-Transplant Surveillance: Insights From Gene Expression &amp; Cell Free DNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:15pm</td>
<td>Shawn M. Marcell, Metamark Genetics</td>
<td>4 Finalists: TBA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A New Age of Proteomic Biomarker Discovery</td>
<td>Winner to be announced at the end of session</td>
<td></td>
</tr>
<tr>
<td>4:30pm</td>
<td>Panel, Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00pm</td>
<td>Closing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Track 1</td>
<td>Track 2</td>
<td>Track 3</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>8:00am</td>
<td>Registration, Breakfast and Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30am</td>
<td></td>
<td>Time Track 1 Track 2 Track 3</td>
<td></td>
</tr>
<tr>
<td>9:00am</td>
<td>The Digital Miasma: Detection and Monitoring of Emerging Infections in the 21st Century</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15am</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00am</td>
<td>Break, Exhibition &amp; Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30am</td>
<td>George Lundberg, ColtabRx (Chair)</td>
<td>Jonathan Sheldon, Oracle Chair</td>
<td></td>
</tr>
<tr>
<td>10:45am</td>
<td>Jodi Halpern, UC Berkeley</td>
<td>Anthony Wiemelt, Penn Medicine &amp; Brian Wells, Penn Medicine</td>
<td>Annai Systems</td>
</tr>
<tr>
<td>11:00am</td>
<td>Patrick McCormick, AIMA</td>
<td>David Haussler, UCSC</td>
<td></td>
</tr>
<tr>
<td>11:15am</td>
<td>Jim Greely, Stanford University</td>
<td>Euan Ashley, Stanford Clinical Genomics Service</td>
<td></td>
</tr>
<tr>
<td>11:30am</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00pm</td>
<td>Lunch, Exhibition &amp; Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm</td>
<td>Fireside chat: Margaret Hamburg, FDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15pm</td>
<td>John West, Personalis, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30pm</td>
<td>David Glazer, Google</td>
<td>Sanjay Joshi, EMC2 (Chair)</td>
<td></td>
</tr>
<tr>
<td>1:45pm</td>
<td>From Data to Meaning: The “So What?” Problem</td>
<td>Biomimicry: Imitation for Innovation</td>
<td></td>
</tr>
<tr>
<td>2:00pm</td>
<td>Martin G. Reese, Omnica Inc.</td>
<td>Emily Leproust, Twist Bioscience</td>
<td></td>
</tr>
<tr>
<td>2:15pm</td>
<td></td>
<td>Towards Practical, High-Capacity, Low-Maintenance Information Storage in Synthesized DNA</td>
<td></td>
</tr>
<tr>
<td>2:30pm</td>
<td>Anne Wojcicki, 23andMe (Chair)</td>
<td>Martin G. Reese, Omnica Inc.</td>
<td></td>
</tr>
<tr>
<td>2:45pm</td>
<td>Tim Sullivan, AncestryDNA</td>
<td>Sanjay Joshi, EMC2 (Chair)</td>
<td></td>
</tr>
<tr>
<td>3:00pm</td>
<td>Harnessing Crowds to Solve the World's Most Difficult Medical Cases</td>
<td>Biomimicry: Imitation for Innovation</td>
<td></td>
</tr>
<tr>
<td>3:15pm</td>
<td>Christina Farr, Thomson Reuters (Moderator)</td>
<td>Euan Thomson, Khosla Ventures</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DAY 3 PROGRAM — January 28, 2015**